Merck Millipore Announces Opening of its GMP Bioproduction Facility in France
News Sep 21, 2012
Merck Millipore has announced the opening of its advanced GMP bioproduction facility in Martillac, France, offering a full, single-use process train to speed a molecule's journey to the clinic.
The site will serve users of Merck Millipore's Provantage™ Biodevelopment and Clinical Supply Solutions, an innovative, "open source" manufacturing option that incorporates the latest technologies for upstream and downstream processes.
The open source approach provides customers with greater control over production.
With a traditional outsourcing model, the customer's process must fit the facility and the contract manufacturer controls the process.
With ProVantage™ Solutions, Merck Millipore develops the process for further use by the customer.
At the new facility, Merck Millipore provides access to proven technologies, process development expertise and validation services, offering a robust template that makes it possible to go from clone selection to GMP product in only 12 months.
The facility offers GMP production of mammalian proteins for pre-clinical to phase II production at the 50 L to 1,250 L scale.
For phase III and commercial production, customers can transfer manufacturing to any location, at any scale.
This freedom brings enhanced flexibility to the molecule development and the manufacturing process.
"Merck Millipore leverages more than 25 years of biomanufacturing experience with 150 molecules in our new facility in France," said Christophe Couturier, Vice President of Services and Solutions, Merck Millipore.
Couturier continued, "As the basis for Provantage™ Solutions, our experts complement customers' internal capabilities in a way that combines the best of in-house production and conventional outsourcing. The end result is increased productivity and an accelerated time to market."
For more information on the new facility and Provantage™ Solutions, please visit www.merckmillipore.com/provantage.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE